China continues industry probe

Share this article:

China's scrutiny of the drug industry continues. The Wall Street Journal reports that Roche announced government authorities from China's State Administration for Industry and Commerce, an agency which oversees marketing and antitrust, visited a site in Hangzhou.

Thursday's news follows last week's announcement that the Ministry of Public Security accused GlaxoSmithKline of bribing HCPs to stimulate prescriptions.

AstraZeneca, Sanofi and Bayer have also come under review over the last year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.